Journal article
Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients
Abstract
BACKGROUND: To study the feasibility of down stage the borderline resectable pancreatic cancer (BRPC) to resectable disease, we reported our institutional results using an intensity-modulated radiation therapy (IMRT) simultaneous integrated boost (SIB) dose escalation approach to improve R0 resectability.
METHODS: We reviewed our past 7 years of experience of using neoadjuvant induction chemotherapy with Gemcitabine followed by concurrent …
Authors
Huang X; Knoble JL; Zeng M; Aguila FN; Patel T; Chambers LW; Hu H; Liu H
Journal
PLOS ONE, Vol. 11, No. 12,
Publisher
Public Library of Science (PLoS)
DOI
10.1371/journal.pone.0166606
ISSN
1932-6203
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyColitisDeoxycytidineFeasibility StudiesFebrile NeutropeniaFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyPancreasPancreatectomyPancreatic NeoplasmsRadiotherapy, Intensity-ModulatedThrombocytopeniaTreatment OutcomeGemcitabine